t e c h n i c a l r e p o r t s
Xenotransplantation models represent powerful tools for the investigation of healthy and malignant human hematopoiesis. However, current models do not fully mimic the components of the human bone marrow (BM) microenvironment, and they enable only limited engraftment of samples from some human malignancies. Here we show that a xenotransplantation model bearing subcutaneous humanized ossicles with an accessible BM microenvironment, formed by in situ differentiation of human BM-derived mesenchymal stromal cells, enables the robust engraftment of healthy human hematopoietic stem and progenitor cells, as well as primary acute myeloid leukemia (AML) samples, at levels much greater than those in unmanipulated mice. Direct intraossicle transplantation accelerated engraftment and resulted in the detection of substantially higher leukemia-initiating cell (LIC) frequencies. We also observed robust engraftment of acute promyelocytic leukemia (APL) and myelofibrosis (MF) samples, and identified LICs in these malignancies. This humanized ossicle xenotransplantation approach provides a system for modeling a wide variety of human hematological diseases.
Over the past several decades, a number of progressively moreimmunodeficient mice strains have been developed. For example, the generation of NSG mice, which bear a targeted deletion of the interleukin (IL)-2 receptor, gamma chain (Il2rg) on the NOD-SCID background, enables the engraftment of many human solid tumors and hematopoietic malignancies 1 . However, even in NSG mice, the level of engraftment of human cells is often low, prompting the development of mouse strains that overexpress or that have targeted insertions of genes encoding human cytokines such as SCF, GM-CSF, IL-3, and TPO [2] [3] [4] [5] .
These mouse strains have been used extensively for the engraftment of human hematopoietic malignancies, particularly AML 6 . However, a large proportion of samples from patients with AML-in particular, the less aggressive subtypes such as those bearing mutations in core binding factors and those that are classified as APL-fail to engraft in NSG mice or do so at low levels that do not mimic human disease [7] [8] [9] . Additionally, some other hematopoietic neoplasms do not engraft at all in the currently available mouse strains. Attempts to generate xenograft models of myelodysplastic syndrome (MDS), myeloproliferative neoplasms (MPNs), and multiple myeloma have met with limited success [10] [11] [12] , although a recent study used a modified NSG engraftment assay involving the co-transplantation of patient-derived mesenchymal stromal cells (MSCs) with their corresponding hematopoietic stem and progenitor cells (HSPCs) to identify MDS-initiating cells 13 . The reasons for the difficulty in engrafting some human hematopoietic neoplasms in mice remain largely unclear, but probably relate to species-specific requirements for environmental factors that mediate hematopoietic cell homing, survival, and expansion.
Hematopoiesis occurs primarily in the BM, where HSCs are localized in specialized microenvironments known as BM niches. In these niches, HSCs reside in close contact and engage in bidirectional interactions with a complex network of cells, including MSCs, osteoblasts, adipocytes, vascular endothelial cells, and Schwann cells 14 . These niches are also co-opted by leukemia cells in hematopoietic malignancies and can support leukemia stem cell (LSC) survival 15, 16 .
Recently, we reported that immature mesenchymal stromal cells from human BM (BM-MSCs), when mixed with extracellular matrix and implanted subcutaneously into the flanks of NSG mice, form a humanized BM microenvironment that is capable of recruiting and supporting the engraftment of mouse hematopoiesis. These ectopic humanized BM niches are also capable of recruiting various human mature blood cell lineages and CD34 + (HSPCs) when human hematopoiesis was established before niche formation 17 . Given that primary malignant hematopoietic cells are dependent on proper BM-niche interactions 18 , we speculated that providing a humanized microenvironment with a supply of human niche factors, as compared to unmanipulated NSG mouse BM, would be sufficient to facilitate superior engraftment and the growth of malignant human hematopoietic cells. Here we show that this is indeed the case: human BM-MSC-derived ossicles (ectopic bone organoid composed of human bone, stroma and hematopoietic tissue), when compared to unmanipulated NSG mouse BM, enable robust and superior engraftment of hematopoietic cells from patients with acute leukemias and other hematopoietic disorders.
RESULTS

Human HSPCs engraft in human BM-MSC-derived ossicles
To establish a xenotransplantation system for healthy and malignant human hematopoietic cells, we generated humanized BM niches in NSG mice in vivo 17 (Fig. 1a and Supplementary Fig. 1a-f , for a detailed protocol for humanized ossicle formation). Subcutaneous transplantation of human BM-MSCs, admixed with extracellular matrix (up to four transplants per mouse), results in the formation of a humanized BM microenvironment within an ossicle after 8-10 weeks. Transplanted cells undergo endochondral ossification in situ and form a marrow cavity, with concomitant invasion of mouse hematopoietic tissue, as indicated by a visible dark-purple color change ( Fig. 1a and Supplementary Fig. 1e , left). The daily administration of an anabolic dose of human parathyroid hormone (40 µg/kg) for 28 d after BM-MSC transplantation resulted in a significant increase in the weight of the humanized ossicles, as compared to untreated mice (mean ± s.d.; 121.9 ± 35.6 mg versus 74.9 ± 29.6 mg; P < 0.001, Supplementary  Fig. 1f ) 19, 20 . To confirm the human origin of ossicle bone and stromal niche elements, BM-MSCs were transduced with lentivirus encoding green fluorescent protein (GFP). Fluorescence microscopy revealed GFP + cells residing both within the bone structures and within the marrow space of mature ossicles (Supplementary Fig. 1h ). 8-10 weeks after subcutaneous implantation, when hematopoietic areas were detectable within the ossicle by visual inspection (development of a purple hue within the ossicle; Supplementary Fig. 1e, left) , ossiclebearing NSG mice were conditioned with sublethal irradiation, and human hematopoietic cells were injected either intravenously or transcutaneously directly into the ossicle (Fig. 1a and Supplementary  Fig. 1e,f) . Because of the easily accessible subcutaneous location, human hematopoietic engraftment in the ossicles can be monitored by serial aspiration and flow cytometry, and histologic assessments performed at the time that the mice are euthanized (Fig. 1a and Supplementary Fig. 1e,f) .
To investigate whether the humanized niches can support human hematopoiesis, we first performed intravenous transplantation of human cord-blood-derived CD34 + HSPCs in mice bearing ossicles. In separate mice, we performed direct intraossicle injection into one ossicle of up to four per mouse. Independently of the transplantation route or the human donor, human CD45 + cells, including both CD19 + lymphoid cells and CD33 + myeloid cells, were detected in the humanized ossicles as early as 4 weeks after transplantation (Supplementary Fig. 2a ). Subsequent aspirates taken at 7-8 weeks and 17-18 weeks after transplantation revealed clear engraftment of human hematopoietic cells in all ossicles analyzed (Fig. 1b,c and Supplementary Fig. 2b ). Human engraftment levels were higher in directly injected ossicles than in the BM of mice that received CD34 + HSPCs through intravenous transplantation (mean ± s.d.; 7-8 weeks, 86.0 ± 9.6% versus 21.2 ± 26.3%; P = 0.1; 17-18 weeks, 90.1 ± 11.6% versus 52.1 ± 26.6%; P = 0.06) (Fig. 1c) . Human engraftment levels were also significantly higher in directly injected ossicles than in the noninjected ossicles or the BM of the same mice, whose engraftment was indicative of homing of HSPCs from the injected ossicle to additional sites of hematopoietic niches (mean ± s.d.; 7-8 weeks, 86.0 ± 9.6% versus 21.3 ± 26.5%; P < 0.001, 86.0 ± 9.6% versus 23.5 ± 32.3%; P < 0.05; 17-18 weeks, 90.1 ± 11.6% versus 51.3 ± 28.0%; P < 0.05, 90.1 ± 11.6% versus 39.9 ± 22.8%; P < 0.05) (Fig. 1c) . Finally, 17-18 weeks after the intravenous transplantation of human HSPCs, engraftment was higher in humanized niches than in mouse BM (mean ± s.d.; 70.7 ± 27.3% versus 52.1 ± 26.8%; P < 0.05) (Fig. 1c) .
At 17-18 weeks after transplantation, we identified mature neutrophils, eosinophils, monocytes, mast cells, and conventional and plasmacytoid dendritic cells, as well as low levels of T cells (<4%), natural killer (NK) cells (<0.2%) and variable numbers of cells committed to the megakaryocyte lineage as well as nucleated-erythroid precursors, in the humanized ossicle niches. As expected, the majority of B cells in the ossicles were immature B cell precursors, and the mature B cells were polyclonal for the expression of immunoglobulin light chains kappa and lambda ( Supplementary Fig. 2c-g ).
Humanized ossicle niches retained and maintained human HSPC populations, including HSCs, multipotent progenitors (MPPs), lymphoid-primed multipotent progenitors (L-MPPs), common myeloid progenitors (CMPs), granulocyte-macrophage progenitors (GMPs), and megakaryocyte-erythroid progenitors (MEPs), for up to 23 weeks ( Supplementary Fig. 2h,i) . Finally, the presence of functional, selfrenewing HSCs within the ossicles was confirmed by the successful engraftment of ossicle-derived cells in secondary recipients with and without established humanized ossicles (Supplementary Fig. 2j ).
Leukemia cells engraft in human BM-MSC-derived ossicles
Next, we investigated the engraftment of primary human acute leukemia cells, both AML and acute lymphoblastic leukemia (ALL), through direct intraossicle injection (see Supplementary Tables 1 and 2 for patient sample information). In the first case, we directly injected 10,000 AML blasts into each ossicle and tracked leukemia engraftment in the transplanted ossicle, as well as in the corresponding mouse BM. Transplanted ossicles exhibited a high level of leukemic engraftment at 12 weeks after transplantation, with >95% CD45 low CD33 + leukemic blasts in all ossicles, and leukemic egress from the humanized ossicles led to a high burden of leukemia in the mouse BM (Fig. 1d,e) . Intraossicle transplantation of a diverse cohort of AML samples demonstrated leukemia engraftment in 13 of 15 samples, with 12 out of 13 achieving >95% human leukemic chimerism in the transplanted ossicles ( Table 1) . Moreover, the intravenous transplantation of ossicle-bearing mice led to >80% leukemic engraftment in the ossicles for four of four AML samples ( Table 1 ). In addition to AML, both patient-derived B cell ALL (B-ALL) and T cell ALL (T-ALL) cells engrafted at high levels in the ossicles after 8-11 weeks; eventually, the BM of mice that had received injections was completely taken over by human CD45 + CD19 + cells or by CD45 + CD3 + cells, respectively (Fig. 1d,e) .
The high frequency and level of engraftment upon direct intraossicle injection suggests that the humanized ossicle niches are superior to mouse BM for the engraftment of human AML. To make direct comparisons, we identified four samples that engrafted poorly upon intravenous transplantation into unmanipulated NSG mice, with either low chimerism or delayed kinetics ( Table 1) . 1 × 10 6 primary AML blasts from each of these samples were either (i) directly injected into one ossicle per mouse, (ii) transplanted intravenously into mice bearing up to four ossicles, or (iii) transplanted intravenously into unmanipulated NSG mice (Fig. 2a) . The kinetics and burden of CD45 + CD33 + leukemia cell engraftment were evaluated by flow cytometry in all ossicles and in the mouse BM every 4-6 weeks, starting at 8 weeks after transplantation (Fig. 2a,b and Supplementary  Figs. 3 and 4) . At 8 weeks post-transplantation, a high leukemia burden npg t e c h n i c a l r e p o r t s was detected in directly injected humanized ossicles, whereas there was almost undetectable engraftment in the BM of unmanipulated NSG mice (mean ± s.d.; 89.6 ± 10.4% versus 2.1 ± 4.6%; P < 0.0001) (Fig. 2b) . Leukemia cells that initially engrafted in humanized ossicles after direct injection preferentially disseminated to nontransplanted ossicles rather than to the BM of the same mouse, over the course of 8-24 weeks after transplantation (mean ± s.d. at 8 weeks, 22.1 ± 26.9% versus 4.6 ± 3.9%; P = 0.09; 12-13 weeks, 74.1 ± 30.4% versus 30.37 ± 40.9%; P < 0.05; 18-24 weeks, 88.5 ± 17.7% versus 60.8 ± 33.6%; P < 0.05 (Fig. 2b) . Histological analysis 8 weeks after transplantation recapitulated the flow cytometry results, demonstrating high human CD45 + leukemia cell burden in the directly injected ossicles, and it revealed low-level engraftment and repopulation in the nontransplanted ossicles of the same mice (Fig. 2c) . In the nontransplanted ossicles, human leukemia cells were almost exclusively localized to the endosteal paratrabecular regions that have previously been demonstrated to be preferred niches for both normal HSCs and AML LSCs 15, 21 .
A similar preferential engraftment of the humanized niches was observed in intravenously injected mice bearing ossicles. At 8 weeks after transplantation, all ossicles were engrafted with human leukemia cells, whereas the mouse BM showed significantly less engraftment, and in some cases, even a complete absence of human cells (mean ± s.d.; 8 weeks, 14.4 ± 19.1% versus 2.5 ± 1.8%; P < 0.01) (Fig. 2a,b and Supplementary Figs. 3 and 4) . Subsequent analysis performed at 12-13 weeks and 18-24 weeks after transplantation demonstrated a continuous statistically significant increase in engraftment in the ossicles, as compared to the mouse BM, reaching near-complete replacement of mouse hematopoiesis in most ossicles by 12-13 weeks (Fig. 2b) . By 18-24 weeks, the leukemia cell burden in the BM of mice without humanized ossicles was significantly lower than engraftment in the ossicles after intravenous injection (mean ± s.d.; 18-24 weeks. 13.4 ± 20.1% versus 89.5 ± 14.1%; P < 0.0001). Notably, the presence of humanized ossicles eventually increased the engraftment of human leukemia in the BM of the same mouse relative to that in unmanipulated mice (mean ± s.d.; 18-24 weeks, 48.0 ± 33.2% versus 13.4 ± 20.1%; P < 0.001). As expected, histological analysis demonstrated effacement of the ossicle marrow cavity with human AML cells that showed typical morphological features of myeloid blasts ( Supplementary  Fig. 5a,b) , and molecular analysis identified leukemia-associated mutations and/or translocations in the engrafted cells ( Supplementary  Fig. 5c and Supplementary Table 3) .
With these four AML samples, the absolute number of leukemia cells recoverable from humanized ossicle niches in a single mouse (four ossicles per mouse) was significantly higher than the number of cells that could be isolated from the corresponding mouse BM. We recovered an average of 5.8 ± 1.5 × 10 7 (mean ± s.d.; SU306, 5.4 ± 0.4 × 10 7 ; SU480, 5.2 ± 0.9 × 10 7 ; SU532, 5.8 ± 0.1 × 10 7 ; SU582, 5.0 ± 1.1 × 10 7 ) human leukemia cells, combined from all four explanted ossicles of mice transplanted with samples SU306, SU480, SU532, and SU582. By contrast, absolute leukemia cell counts recoverable from total mouse 
BM were significantly lower, with an average of 1.6 ± 2.3 × 10 7 human leukemia cells, and varied depending on engraftment level (P < 0.0001 for all samples combined, unpaired Student's t test; SU306, 8.9 ± 1.5 × 10 6 ; SU480, 3.7 ± 2.7 × 10 7 ; SU532, 1.4 ± 2.6 × 10 7 ; SU582, 5.9 ± 4.8 × 10 6 ; Supplementary Fig. 5d ).
Engrafted cells in humanized ossicles recapitulate the original subclonal architecture Recent work has suggested that conventional NSG mouse xenograft assays do not fully recapitulate the clonal heterogeneity of patient samples. As a result, engrafting subclones may be distinct from the dominant founding or relapse clones, presumably because of selective pressure imparted by the mouse BM microenvironment 22 . We investigated the clonal composition of human AML cells engrafted in the humanized ossicle niches through targeted re-sequencing of known leukemia mutations in four of the engrafted normal karyotype cases. In all samples analyzed (SU306, SU480, SU532, and SU582), we detected the same variants (SNPs and indels) at similar variant allele frequencies in the primary patient samples and in the ossicle-engrafted leukemia cells at 18-24 weeks after transplantation (Supplementary Fig. 5c ). Notably, AML blasts transplanted by direct intraossicle injection most closely recapitulated the clonal heterogeneity of the original patient blasts, whereas cells that engrafted in the mouse BM after intravenous transplantation tended to show variable variant allele frequencies (Supplementary Fig. 5c , bottom) For example, at sample SU532, a canonical mutation in the NPM1 gene was detected at similar levels in both the original blasts and the cells from the engrafted ossicles; however, a subclone without this NPM1 mutation engrafted the mouse BM of animals that received intravenous transplants, demonstrating that engraftment of the original clone occurred only in the ossicle model.
Ossicle transplantation reveals a higher frequency of leukemia-initiating cells
Original studies using limiting-dilution xenograft assays suggested that LICs in AML were rare, comprising 1:10,000 or fewer cells 23, 24 . npg t e c h n i c a l r e p o r t s nature medicine VOLUME 22 | NUMBER 7 | JULY 2016 8 1 7
To determine whether transplantation of AML cells into a humanized microenvironment, relative to unmanipulated NSG mice, reveals a higher frequency of LICs, we conducted limiting-dilution assays with two AML samples using both direct intraossicle transplantation and direct intrafemoral transplantation in unmanipulated NSG mice. Cells from case SU028 demonstrated engraftment in the ossicles in all mice transplanted with as few as 100 cells, whereas no engraftment was detected by intrafemoral transplantation with 100 cells (Fig. 3a,b) . In fact, we observed leukemic engraftment from the transplantation of a single SU028 CD34 + CD38 − leukemic blast in a humanized ossicle (Fig. 3c) , resulting in an approximately 27-fold increase in the frequency of LICs, to 1:20 cells (Fig. 3b and Supplementary Table 4) . In the case of SU048, complete engraftment (>95%) was detected in the injected ossicles from as few as 500 cells, as compared to very low engraftment (<1%) in mice transplanted intrafemorally with 1,000 cells, which resulted in a tenfold increase in LIC frequency, to 1:271 cells (Fig. 3d,e and Supplementary Table 4) .
Engraftment of APL cells in ossicles
Transplantation of human APL cells into immunocompromised mice has so far met with limited success, resulting in low to no detectable engraftment 9, 24 . Given that humanized ossicle niches show superior engraftment of non-APL AML samples, we attempted to induce the engraftment of primary human APL cells by direct intraossicle injection. We injected 0.9 × 10 6 -1.4 × 10 6 mononuclear cells from primary APL samples into humanized ossicles and monitored engraftment over time. As early as 6-8 weeks after transplantation, we detected CD45 + CD33 + leukemia cells in injected ossicles (mean ± s.d.; SU589, 41.2 ± 27.4%; SU490, 21.5 ± 8.2%; SU748, 5.1 ± 7.1%; SU718, 0.3 ± 0.5%) (Fig. 4a,b and Supplementary Fig. 6a-c) . 
npg t e c h n i c a l r e p o r t s
In two of four samples (SU490 and SU589), although the transplanted cells initially gave rise to both lymphoid and myeloid cells, indicative of normal hematopoietic engraftment, at 6 weeks after transplantation, the eventual outgrowth and proliferation of APL blasts resulted in an almost complete engraftment of the ossicle with leukemia cells at 12-24 weeks (mean ± s.d.; SU589, 94.1 ± 8.5%; SU490, 90.5 ± 5.6%; SU748, 78.9 ± 32.3%; SU718, 97.2 ± 1.3%) (Fig. 4a,b and Supplementary Fig. 6a-c) , but much lower engraftment of leukemic cells was detected in the mouse BM (Fig. 4a,b) . As shown by fluorescence in situ hybridization (FISH), myeloid cells isolated from the engrafted ossicles harbored the human promyelocytic leukemiaretinoic acid receptor-α (PML-RARA) oncogene translocation that is characteristic of APL (Fig. 4c and Supplementary Fig. 6a-c) . Gross examination of the explanted ossicles revealed the formation of subcutaneous granulocytic sarcomas or chloromas, as indicated by their yellow-green appearance, and histological analysis of engrafted ossicles identified densely packed immature blasts morphologically resembling promyelocytes (Fig. 4d) . May-Gruenwald-Giemsa (MGG) staining confirmed the presence of azurophilic granules or characteristic cerebriform, bilobed nuclei pathognomonic for the microgranular variant of APL (Fig. 4d) .
The successful engraftment of primary human APL cells provided us with the opportunity to investigate the immunophenotypic identity of LICs in this disease, which has been a point of controversy in the field 25 . First, we isolated a CD34 + CD38 − CD45RA − fraction (containing HSCs and MPPs in healthy BM) from primary APL samples, and we injected these cells or bulk APL cells directly into humanized ossicles. In contrast to bulk cells that transiently (6-8 weeks after transplantation) gave rise to lymphoid and myeloid cells, before being replaced by 100% myeloid cells harboring the PML-RARA translocation (Fig. 4a) , transplanted HSC and MPP produced normal B cells and myeloid cells that lacked the PML-RARA translocation for up to 24 weeks (Supplementary Fig. 6d,e) , which suggests that LIC activity in APL resides in a cell that is downstream of the HSC and MPP stage. This idea was further supported by FISH analysis of subpopulations that were isolated from several primary APL samples, which demonstrated that HSCs, MPPs, CMPs, and MEPs lacked the PML-RARA translocation in all samples analyzed (Supplementary Table 5 ). Fig. 6e) . Thus, LICs in APL do not reside in HSCs or MPPs, and probably reside in a lineagecommitted progenitor.
Ossicles facilitate engraftment of myelofibrosis Myelofibrosis (MF), an MPN that is commonly associated with the V617F mutation in Janus kinase 2 (JAK2 V617F ) and with calreticulin (CALR) mutations [26] [27] [28] [29] , has shown only limited engraftment in conventional xenograft models [30] [31] [32] . We examined the ability of humanized ossicles to facilitate the engraftment of MF (Supplementary Table 6 for patient sample information) by directly injecting FACS-purified CD34 + cells from patient samples into ossicles. Transplantation of as few as 50,000 CD34 + cells resulted in robust engraftment (up to >95%) of human hematopoietic cells for up to 19 weeks after transplantation (Fig. 5a,b) . Notably, the engrafted cell population consisted mainly of CD33 + myeloid cells, with minimal to absent reconstitution of B cells, which are the predominant population in mice engrafted with healthy human CD34 + cells (Fig. 5c and Supplementary Fig. 2b for healthy human CD34 + cells). Allele-specific quantitative real-time PCR demonstrated that engrafted human CD45 + CD33 + myeloid cells at 8-19 weeks after transplantation harbored the JAK2 V617 mutation in four of four samples, indicating that they were derived from the transplanted MF cells (Fig. 5d) . The JAK2 V617F mutated allele burden in the engrafted cells was nearly identical to the allele burden in the HSPCs and myeloid cells isolated from the primary sample in both homozygous (SU094.D, SU415) and heterozygous (SU180, Fig. 7a ). For sample SU239B cells harboring a type 1 CALR mutation (52-bp deletion), we confirmed the presence of the mutation in the engrafted myeloid cells by Sanger sequencing (Supplementary Fig. 7d) . Consistently with the engraftment of MF-initiating cells, histological analysis identified an increase in reticulin fibers within the engrafted humanized ossicles (Fig. 5e) .
The successful engraftment of primary human MF cells provided the opportunity to investigate LICs in this disease; these cells have long been hypothesized to reside in the HSC compartment 33 . We first fractionated CD34 + cells from MF samples into CD34 + CD38 + and CD34 + CD38 lo/− subfractions and transplanted each directly into multiple humanized ossicles (n = 4-7 per sample). In all three samples tested, the engraftment of human cells was observed exclusively in ossicles transplanted with CD34 + CD38 −/lo cells (n = 19 ossicles), showing no engraftment of CD34 + CD38 + cells (n = 12 ossicles), despite the fact that higher numbers of these cells were transplanted (Supplementary Table 7 ). We further fractionated the CD34 + CD38 low/− cells from sample SU482 and SU239.B into HSCs and MPPs 34 , and tested their engraftment potential through direct intraossicle injection. As a negative control, we also transplanted CMPs from the CD34 + CD38 + fraction (Supplementary Table 5 ). 8 weeks after transplantation, human CD45 + cells were detectable only in ossicles transplanted with HSCs, not with MPPs or CMPs ( Fig. 5f and Supplementary Fig. 7b) , and the engrafted myeloid cells harbored the JAK2 V617F mutation or the type 1 CALR mutation (52-bp deletion) (Supplementary Fig. 7c,d) . These results formally demonstrate that MF-initiating cells reside exclusively in the HSC compartment.
DISCUSSION
Here we demonstrate that a xenotransplantation system based on the in situ subcutaneous generation of human BM-MSC-derived ossicles and the formation of a humanized BM microenvironment supports normal and malignant hematopoiesis more effectively than existing xenotransplantation models. Previous xenotransplantation studies suggested that AML LICs are enriched in the CD34 + CD38 − fraction of leukemic blasts and are rare cells, occurring at a frequency on the order of 1:10,000 to 1:100,000 (refs. 23,24) . More recent studies suggest that LICs are more frequent, and that they can be found in additional immunophenotypically defined subpopulations 7, 35, 36 . Here we provide evidence that the frequency of LICs is substantially higher if evaluated by xenotransplantation into a humanized niche, as compared to the BM of naïve NSG mice, which suggests that the LIC frequency in AML is crucially dependent on leukemia cell-niche interactions.
The identification of disease-initiating cells in APL has been hampered by the lack of a xenotransplantation model. In APL, the nature of the hematopoietic cell that is the target of the disease-causing chromosomal translocation is a matter of debate 25 : in vitro studies have implicated immature compartments that are able to produce myeloid and erythroid output 37 , whereas other reports support the concept that APL arises from committed myeloid progenitors [38] [39] [40] . Here we report successful fulminant engraftment of PML-RARA-positive human APL cells in humanized ossicles, and the identification of APL-initiating cells in an aberrant CD34 −/lo GMP-like population. This further supports the notion that APL is a disease that arises from committed myeloid cells and that probably does not involve immature HSPCs. Our experiments still leave open the possibility that CD34 − cells, which are the majority of cells in most APL cases, also contain disease-initiating cells. These results are consistent with mouse models that drive the expression of PML-RAR-α from a myeloid lineage-restricted promoter, resulting in an APL-like disease 41, 42 . The absence of the PML-RARA translocation in human HSCs obtained from APL patient samples is surprising, given that PML-RAR-α on its own induces myeloid commitment, rather than self-renewal, in hematopoietic progenitors such as GMPs 43 . In contrast to a recently published report 44 demonstrating the establishment of APL from transduced cord-blood-derived CMPs, we did not identify PML-RARA fusion events in FACS-purified CMPs from primary patient samples. How PML-RAR-α initiates a self-renewal program in human progenitors to cause APL is an important question for further studies of APL pathogenesis.
Our humanized ossicle model, similarly to APL, facilitates robust engraftment of primary human MF cells, which has only been of limited success with peripheral blood cells in conventional NSG models 32, 45 . Unlike studies of AML, where disease-initiating cells arise from progenitors 36 , we show here that MF-initiating cells reside in the HSC compartment, because transplantation of these cells-but not of MPPs or CMPs-results in the engraftment of JAK2 V617F or CALR-mutated cells. Notably, the progeny of MF HSCs exhibited a pronounced skewing toward the myeloid lineage, which suggests that the JAK2 V617F and CALR mutations drive a differentiation program that blocks lymphoid development in favor of myeloid cells.
Recently, several newly developed xenotransplantation models have been reported for improved engraftment of human hematopoietic cells, including modified NSG strains with overexpression or knock-in of human cytokines 2,4,5,46,47 , co-transplantation of hematopoietic cells with mesenchymal stromal cells 13 , or transplantation of engineered bioscaffolds designed to resemble human BM niches 48 . Although each of these approaches has advantages over conventional NSG mouse models, none has demonstrated the rapid and high leukemic engraftment observed with our humanized ossicle niche model, in which direct intraossicle injection resulted in >95% leukemic chimerism in nearly all engrafting leukemia samples tested. These observations suggest that our approach more faithfully models human disease and provides a superior system for further investigation into human leukemia pathogenesis, leukemia cell-niche interactions, and response to therapeutics.
METHODS
Methods and any associated references are available in the online version of the paper.
Statistics. P values were calculated using nonparametric two-tailed MannWhitney test or unpaired Student's t test in Prism version 6 (GraphPad Software, Inc., La Jolla, CA). A P value of <0.05 was considered to be statistically significant. Limiting-dilution data are presented as the estimated limitingdilution frequency ±95% confidence interval. Limiting-dilution analysis was done with the Extreme Limiting Dilution Analysis (ELDA) software provided by the Walter and Eliza Hall Institute of Medical Research Bioinformatics.
